Nikko Asset Management Americas’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
Other funds holding TXG
AIM
VPM
QCM
VCM
Nikko Asset Management Americas's TXG Position: Q1 2026 in Review
Nikko Asset Management Americas reduced its 10x Genomics (TXG) stake by 7% in Q1 2026, selling an estimated $7.64M and leaving 5,104,178 shares worth $108M. The position accounts for 1.53% of the portfolio, ranked #18.
Nikko Asset Management Americas first reported a position in TXG in Q2 2020 and has held it in 24 quarters since. The position peaked at $299M in Q2 2021. 330 funds tracked by Wall St. Rank hold TXG as of Q1 2026.
- Nikko Asset Management Americas held 5,104,178 shares of 10x Genomics worth $108M as of Q1 2026.
- Nikko Asset Management Americas sold 381,975 10x Genomics shares in Q1 2026, an estimated $7.64M.
- 10x Genomics made up 1.53% of Nikko Asset Management Americas's portfolio in Q1 2026, its #18 holding.
- Nikko Asset Management Americas first reported a position in 10x Genomics in Q2 2020 and has held it in 24 quarters since.
- Nikko Asset Management Americas's 10x Genomics position peaked at $299M in Q2 2021.
- 330 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.
Based on Nikko Asset Management Americas's 13F filing for Q1 2026, filed 7 May 2026.